Publications by authors named "John Culpepper"

Reductive stress is characterized by an excess of cellular electron donors and can be linked with various human pathologies including cancer. We developed melanoma cell lines resistant to reductive stress agents: rotenone (ROT), n-acetyl-L-cysteine, (NAC), or dithiothreitol (DTT). Resistant cells divided more rapidly and had intracellular homeostatic redox-couple ratios that were shifted towards the reduced state.

View Article and Find Full Text PDF
Article Synopsis
  • - Recent therapies for malignant melanoma show promise, but most patients develop resistance, highlighting the need for new drug targets focused on redox homeostasis and lipid peroxidase pathways to improve treatment outcomes.
  • - Researchers found that microsomal glutathione S-transferase 1 (MGST1), a specific enzyme, is highly expressed in drug-resistant melanomas and plays a crucial role in tumor spread and response to therapy.
  • - Reducing MGST1 levels in melanoma cells increased oxidative stress and made them more susceptible to immune attack and anticancer drugs, leading to reduced metastasis and improved survival in mouse models.
View Article and Find Full Text PDF

Recent advancements in the treatment of melanoma are encouraging, but there remains a need to identify additional therapeutic targets. We identify a role for microsomal glutathione transferase 1 (MGST1) in biosynthetic pathways for melanin and as a determinant of tumor progression. Knockdown (KD) of MGST1 depleted midline-localized, pigmented melanocytes in zebrafish embryos, while in both mouse and human melanoma cells, loss of MGST1 resulted in a catalytically dependent, quantitative, and linear depigmentation, associated with diminished conversion of L-dopa to dopachrome (eumelanin precursor).

View Article and Find Full Text PDF

Multiple myeloma (MM) cells have high rates of secretion of proteins rich in disulfide bonds and depend upon compartmentalized redox balance for accurate protein folding. The proteasome inhibitor bortezomib (Btz) is a successful frontline treatment for the disease, but its long-term efficacy is restricted by the acquisition of resistance. We found that MM cell lines resistant to Btz maintain high levels of oxidative stress and are cross resistant to endoplasmic reticulum (ER) stress-inducing agents thapsigargin (ThG), and tunicamycin (TuM).

View Article and Find Full Text PDF